Skip to main content
Erschienen in:

23.03.2020 | Original Research Article

Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma

verfasst von: Iris Y. Sheng, Claudia Marcela Diaz-Montero, Patricia Rayman, Wei Wei, James H. Finke, Jin S. Kim, Paul G. Pavicic Jr., Marcelo Lamenza, Donna Company, Andrew Stephenson, Steven Campbell, George Haber, Byron Lee, Omar Mian, Timothy D. Gilligan, Brian I. Rini, Jorge A. Garcia, Petros Grivas, Moshe C. Ornstein

Erschienen in: Targeted Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Myeloid-derived suppressor cells (MDSCs) were linked to pathologic stage in bladder urothelial carcinoma (UC). Neutrophil lymphocyte ratio (NLR) is an inflammatory biomarker with a prognostic role in metastatic (m)UC.

Objective

We hypothesized that MDSC levels correlate with NLR and overall survival (OS) in mUC.

Patients and methods

MDSCs were measured in blood samples from patients with mUC in fresh unfractionated whole blood (WB) and peripheral blood mononuclear cells (PBMC) by flow cytometry and defined as LinloCD33+/HLADR- (Total MDSC). MDSC subsets were defined as polymorphonuclear (PMN-MDSC: CD15+/CD14−), monocytic (M-MDSC: CD15−/CD14+), and uncommitted (UNC-MDSC: CD15−/CD14−). MDSC populations were presented as a percentage of live nucleated blood cells. Spearman’s rank correlation assessed correlations between MDSC and NLR. Kaplan–Meier curves and log-rank test estimated OS from the time of MDSC collection to last follow-up or date of death.

Results

Of the 76 patients, 78% were men and 43% were never smokers with a median age of 69 years (range 31–83); 72% had pure UC and 76% had lower tract UC. Prior therapies included intravesical therapy (22%), neoadjuvant chemotherapy (30%), cystectomy or nephroureterectomy (55%). Median follow-up for all patients was 12 months (0.6–36.5). PMN-MDSC was the predominant subset in WB and PBMC. There was significant correlation between individual MDSC subsets in WB and PBMC (p ≤ 0.001). Both WB UNC-MDSC/PMN-MDSC ratios (rho = − 0.27, p = 0.03) and PBMC UNC-MDSC/PMN-MDSC (rho = − 0.28, p = 0.02) were negatively correlated with NLR. Median OS was 17.7 months (95% CI: 11.0–NE). Overall 1-year and 3-year survival rates were 0.60 (95% CI 0.49–0.73) and 0.15 (95% CI 0.03–0.67), respectively. Higher WB UNC-MDSC levels (HR 3.78, p = 0.0022) and higher NLR (HR 2.6, p = 0.0179) were associated with shorter OS.

Conclusions

Specific MDSC subsets correlate with NLR. Higher WB UNC-MDSC levels and higher NLR were negative prognostic factors. Given the feasibility of serial blood draws, dynamic assessment of MDSC over time and further validation with longer follow-up are warranted.
Literatur
2.
Zurück zum Zitat Andreassen BK, Aagnes B, Gislefoss R, Andreassen M, Wahlqvist R. Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981–2014. BMC Cancer. 2016;16:799.PubMedPubMedCentralCrossRef Andreassen BK, Aagnes B, Gislefoss R, Andreassen M, Wahlqvist R. Incidence and Survival of urothelial carcinoma of the urinary bladder in Norway 1981–2014. BMC Cancer. 2016;16:799.PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Mari A, Campi R, Tellini R, et al. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. World J Urol. 2018;36(2):157–70.PubMedCrossRef Mari A, Campi R, Tellini R, et al. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. World J Urol. 2018;36(2):157–70.PubMedCrossRef
4.
Zurück zum Zitat Mitra AP, Quinn DI, Dorff TB, et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012;109(6):846–54.PubMedCrossRef Mitra AP, Quinn DI, Dorff TB, et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012;109(6):846–54.PubMedCrossRef
6.
Zurück zum Zitat Tang X, Du P, Yang Y. The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis. Int J Clin Oncol. 2017;22(5):817–25.PubMedCrossRef Tang X, Du P, Yang Y. The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis. Int J Clin Oncol. 2017;22(5):817–25.PubMedCrossRef
7.
Zurück zum Zitat Wu S, Zhao X, Wang Y, et al. Pretreatment neutrophil-lymphocyte ratio as a predictor in bladder cancer and metastatic or unresectable urothelial carcinoma patients: a pooled analysis of comparative studies. Cell Physiol Biochem. 2018;46(4):1352–64.PubMedCrossRef Wu S, Zhao X, Wang Y, et al. Pretreatment neutrophil-lymphocyte ratio as a predictor in bladder cancer and metastatic or unresectable urothelial carcinoma patients: a pooled analysis of comparative studies. Cell Physiol Biochem. 2018;46(4):1352–64.PubMedCrossRef
11.
Zurück zum Zitat Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012;167(2):195–205.PubMedPubMedCentralCrossRef Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol. 2012;167(2):195–205.PubMedPubMedCentralCrossRef
12.
13.
Zurück zum Zitat Umansky V, Blattner C, Gebhardt C, Utikal J. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines. 2016;4(4):36.PubMedCentralCrossRef Umansky V, Blattner C, Gebhardt C, Utikal J. The role of myeloid-derived suppressor cells (MDSC) in cancer progression. Vaccines. 2016;4(4):36.PubMedCentralCrossRef
14.
Zurück zum Zitat Fleming V, Hu X, Weber R, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol. 2018;9:398.PubMedPubMedCentralCrossRef Fleming V, Hu X, Weber R, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol. 2018;9:398.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Mantovani A. The growing diversity and spectrum of action of myeloid-derived suppressor cells. Eur J Immunol. 2010;40(12):3317–20.PubMedCrossRef Mantovani A. The growing diversity and spectrum of action of myeloid-derived suppressor cells. Eur J Immunol. 2010;40(12):3317–20.PubMedCrossRef
16.
Zurück zum Zitat Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59.PubMedCrossRef Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59.PubMedCrossRef
18.
Zurück zum Zitat Yang G, Shen W, Zhang Y, et al. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget. 2017;8(24):38378–88.PubMedPubMedCentral Yang G, Shen W, Zhang Y, et al. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget. 2017;8(24):38378–88.PubMedPubMedCentral
19.
Zurück zum Zitat Ornstein MC, Diaz-Montero CM, Rayman PA, et al. Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI). J Clin Oncol. 2017;35(15_suppl):e16005.CrossRef Ornstein MC, Diaz-Montero CM, Rayman PA, et al. Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI). J Clin Oncol. 2017;35(15_suppl):e16005.CrossRef
20.
Zurück zum Zitat Tzeng A, Diaz-Montero CM, Rayman PA, et al. Immunological correlates of response to immune checkpoint inhibitors in metastatic urothelial carcinoma. Target Oncol. 2018;13(5):599–609.PubMedCrossRef Tzeng A, Diaz-Montero CM, Rayman PA, et al. Immunological correlates of response to immune checkpoint inhibitors in metastatic urothelial carcinoma. Target Oncol. 2018;13(5):599–609.PubMedCrossRef
21.
Zurück zum Zitat Formica V, Luccchetti J, Cunningham D, et al. Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Med Oncol. 2014;31(9):166.PubMedCrossRef Formica V, Luccchetti J, Cunningham D, et al. Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients. Med Oncol. 2014;31(9):166.PubMedCrossRef
22.
Zurück zum Zitat Zhu Z, Shen Z, Xu C. Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediat Inflamm. 2012;2012:528690.CrossRef Zhu Z, Shen Z, Xu C. Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediat Inflamm. 2012;2012:528690.CrossRef
23.
Zurück zum Zitat Marchioni M, Primiceri G, Ingrosso M, et al. The clinical use of the neutrophil to lymphocyte ratio (NLR) in urothelial cancer: a systematic review. Clin Genitourin Cancer. 2016;14(6):473–84.PubMedCrossRef Marchioni M, Primiceri G, Ingrosso M, et al. The clinical use of the neutrophil to lymphocyte ratio (NLR) in urothelial cancer: a systematic review. Clin Genitourin Cancer. 2016;14(6):473–84.PubMedCrossRef
24.
Zurück zum Zitat Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63(3):247–57.PubMedCrossRef Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63(3):247–57.PubMedCrossRef
25.
Zurück zum Zitat Wu K, Tan M-Y, Jiang J-T, et al. Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: a novel chemoimmunomodulating strategy. Clin Immunol. 2018;193:60–9.PubMedCrossRef Wu K, Tan M-Y, Jiang J-T, et al. Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: a novel chemoimmunomodulating strategy. Clin Immunol. 2018;193:60–9.PubMedCrossRef
26.
Zurück zum Zitat Ornstein MC, Diaz-Montero CM, Rayman P, et al. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. Urol Oncol Semin Orig Investig. 2018;36(9):405–12.CrossRef Ornstein MC, Diaz-Montero CM, Rayman P, et al. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. Urol Oncol Semin Orig Investig. 2018;36(9):405–12.CrossRef
27.
Zurück zum Zitat Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res. 2014;20(6):1601–9.PubMedCrossRef Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res. 2014;20(6):1601–9.PubMedCrossRef
28.
Zurück zum Zitat Lucca I, Jichlinski P, Shariat SF, et al. The neutrophil-to-lymphocyte ratio as a prognostic factor for patients with urothelial carcinoma of the bladder following radical cystectomy: validation and meta-analysis. Eur Urol Focus. 2016;2(1):79–85.PubMedCrossRef Lucca I, Jichlinski P, Shariat SF, et al. The neutrophil-to-lymphocyte ratio as a prognostic factor for patients with urothelial carcinoma of the bladder following radical cystectomy: validation and meta-analysis. Eur Urol Focus. 2016;2(1):79–85.PubMedCrossRef
29.
Zurück zum Zitat Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother. 2012;61(8):1155–67.PubMedCrossRef Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother. 2012;61(8):1155–67.PubMedCrossRef
31.
Zurück zum Zitat Tesi RJ. MDSC; the most important cell you have never heard of. Trends Pharmacol Sci. 2019;40(1):4–7.PubMedCrossRef Tesi RJ. MDSC; the most important cell you have never heard of. Trends Pharmacol Sci. 2019;40(1):4–7.PubMedCrossRef
32.
Zurück zum Zitat Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating myeloid derived suppressor cells (MDSC) that accumulate in premalignancy share phenotypic and functional characteristics with MDSC in cancer. Front Immunol. 2019;10:1401.PubMedPubMedCentralCrossRef Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating myeloid derived suppressor cells (MDSC) that accumulate in premalignancy share phenotypic and functional characteristics with MDSC in cancer. Front Immunol. 2019;10:1401.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Bruger AM, Dorhoi A, Esendagli G, et al. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother. 2019;68(4):631–44.PubMedCrossRef Bruger AM, Dorhoi A, Esendagli G, et al. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother. 2019;68(4):631–44.PubMedCrossRef
34.
Zurück zum Zitat Blidner AG, Salatino M, Mascanfroni ID, et al. Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments. J Immunol. 2015;194(7):3452–62.PubMedCrossRef Blidner AG, Salatino M, Mascanfroni ID, et al. Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments. J Immunol. 2015;194(7):3452–62.PubMedCrossRef
35.
Zurück zum Zitat Cassetta L, Baekkevold ES, Brandau S, et al. Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother. 2019;68(4):687–97.PubMedPubMedCentralCrossRef Cassetta L, Baekkevold ES, Brandau S, et al. Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother. 2019;68(4):687–97.PubMedPubMedCentralCrossRef
Metadaten
Titel
Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma
verfasst von
Iris Y. Sheng
Claudia Marcela Diaz-Montero
Patricia Rayman
Wei Wei
James H. Finke
Jin S. Kim
Paul G. Pavicic Jr.
Marcelo Lamenza
Donna Company
Andrew Stephenson
Steven Campbell
George Haber
Byron Lee
Omar Mian
Timothy D. Gilligan
Brian I. Rini
Jorge A. Garcia
Petros Grivas
Moshe C. Ornstein
Publikationsdatum
23.03.2020
Verlag
Springer International Publishing
Erschienen in
Targeted Oncology / Ausgabe 2/2020
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-020-00707-z

Neu im Fachgebiet Onkologie

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.